Summary
Using X-ray fluorescence spectrometry, platinum concentrations were determined in autopsy tissue samples from 12 patients who had received cis-diamminedichloroplatinum (DDP) 20–120 mg/m2 up to 6 months antemortem. Tissue platinum concentrations were highest in liver (0.5–3.7 μg/g wet weight), prostate (1.6–3.6 μg/g), and kidney (0.4–2.9 μg/g), somewhat lower in bladder, muscle, testicle, pancreas, and spleen, and lowest in bowel, adrenal, heart, lung, cerebrum, and cerebellum, Platinum concentrations in tumors were generally somewhat lower than the concentration in the organ in which the tumor was located, with the exception of intracerebral tumors. Different metastatic sites in the same patient had substantially different platinum concentrations and hepatic metasutases had the highest concentrations. Intra-arterial administration of drug may augment tissue concentrations of platinum. In a patient undergoing therapeutic abortion 4 days after treatment, the platinum concentration was 0.5 μg/g in the placenta and 0.3 μg/g in the fetus. The data suggest that for in vitro sensitivity testing, DDP concentrations of ≦7 μg/ml should be used.
Similar content being viewed by others
References
Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30: 969–985
Calvo DB III, Patt YZ, Wallace LS, Chuang VP, Benjamin RS, Pritchard JD, Hersh EM, Bodey GP, Mavligit GM (1980) Phase I–II trial of percutaneous intraarterial cis-diamminedichloroplatinum (II) for regionally confined malignancy. Cancer 45: 1278–1283
Dorr RT, Fritz WL (1980) Cancer chemotherapy handbook. Elsevier/North Holland, New York
Douple EB, Richmond RC (1978) Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer 37 [Suppl III]: 98–102
Dristchilo A, Piro AJ, Kelman AD (1979) The effect of cis-platinum on the repair of radiation damage in plateau phase Chinese hamster (V-79) cells. Int J Radiat Oncol Biol Phys 5: 1345–1349
Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, King J (1975) Clinical studies of platinum co-ordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 59: 647–659
LeRoy AF, Lutz RJ, Dedrick RL, Litterst CL, Guarino AM (1979) Pharmacokinetic study of cis-dichlorodiammineplatinum (II) (DDP) in the beagle dog: Thermodynamic and kinetic behaviour of DDP in a biologic milieu. Cancer Treat Rep 63: 59–71
Litterst CL, LeRoy AF, Guarino AM (1979) Disposition and distribution of platinum following parenteral administration of cis-dichlorodiammineplatinum (II) to animals. Cancer Treat Rep 63: 1485–1492
Salmon SE, Hamburger AW, Solhnlen BJ, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298: 1321–1327
Stewart DJ, Benjamin RS, Seifert W, Wallace S, Gutterman JU, Patt Y, Calvo D III, Samuels M, Loo Ti Li (1980) Clinical pharmacology of intraarterial (IA) cis-diamminedichloroplatinum II (DDP). Proc Am Soc Clin Oncol 21: 337
Stewart DJ, Wallace S, Leavens M, Young S, Feun L, Mavligit G, Benjamin R, Freireich E (1981a) Phase I study of intracarotid (IC) cesdiamminedichloroplatinum (DDP) in patients with intracerebral tumors (ICT). Proc Am Assoc Cancer Res 22: 189
Stewart DJ, Leavens M, Luna M, Seifert W, Loo TL, Benjamin RS (1981b) Human central nervous system pharmacology of cis-diamminedichloroplatinum (DDP). Proc Am Soc Clin Oncol 22: 359
Vermoken JB, van der Vijgh WJF, McVie JG, Pinedo HM (1980) Some new pharmacokinetic aspects of cis-diamminedichloroplatinum (DDP). Proc Am Soc Clin Oncol 21: 338
Williams CJ, Whitehouse JMA (1979) Cis-platinum: A new anticancer agent. Br Med J I: 1689–1691
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stewart, D.J., Benjamin, R.S., Luna, M. et al. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemother. Pharmacol. 10, 51–54 (1982). https://doi.org/10.1007/BF00257239
Issue Date:
DOI: https://doi.org/10.1007/BF00257239